

BSW Formulary Update – Following APC Mar 2021 meeting

New additions to the BSWformulary

- [Dienogest 2mg tablets \(Zalkya®\)](#) third line option for the treatment of endometriosis where oral progestogen and/or combined oral contraceptive and/or Mirena have not been effective or are contraindicated. **RED TLS.**
- [Albustix® Protein urinalysis detection strips](#) Added as an option alongside MediTest protein2® for the rare occasions where monitoring for nephritis or nephrotic syndrome is required. **GREEN TLS.**
- [Colecalciferol 10,000unit/ml \(Thorens® oral solution\)](#) added for use (paeds only). **AMBER TLS.** *Please note formulary team are continuing to build and improve the paediatric chapter of the formulary.*

TLS Aligned for BSW

- Pancreatin products: ([Creon capsules](#) and [micro capsules](#) (paeds only); [Pancrex V Powder](#) (those with feeding tubes)) aligned with **AMBER TLS.**
- [Oral Betamethasone 500microgram soluble tablet](#): Existing formulary entry in chapter 6 (endocrine) aligned with **AMBER TLS.** Additional entry made in chapter 12 (ear, nose and oropharynx) for off-label use as a mouthwash and includes supporting guidance for patient counselling so patients are not exposed to unintentionally high doses of steroids. **AMBER TLS.**

New and Updated Prescribing Guidelines

- **Updated** - [BSW Management of Infection Guidance for Primary Care](#). Update incorporates guidance from the NICE Clinical Knowledge Summary for mastitis and covers lactational and non-lactational mastitis and also provides information on breast abscess.
- **Updated** - [BSW Chronic Migraine Pathway for adults](#). Minor update includes additional links to MHRA safety updates for antiepileptic drugs in pregnancy; the section on topiramate use in females of child-bearing potential has been reworded; specific information on galcanezumab and fremenezumab has been replaced with a statement that a local pathway for use of biologics is currently being written in anticipation of the NICE TA for erenumab due for implementation by 8th June 2021.
- **Updated** - [BSW CCG Managing male patients with prostate cancer on LHRH analogues during the COVID-19 pandemic](#). Guidance has been reworded so that the 6 monthly LHRH preparation, Triptorelin pamoate IM (Decapeptyl SR® 22.5mg) is ‘an option’ rather than ‘first line’ treatment. Some smaller practices may not have accessed

appropriate product-specific training. Rewording allows practices to decide whether they remain with their current processes or access training to offer the 6 monthly IM preparations.

Other BSWformulary website updates

- **Immediate-release fentanyl preparations for use in palliative care have been reviewed by palliative care specialist teams for BSW:**
 - Sublingual fentanyl tablets (Abstral®) are first line **AMBER TLS**.
 - Fentanyl nasal spray (PecFent®) is second line **AMBER TLS**.
 - Buccal tablets (Effentora®) and lozenges (Actiq®) have moved to non-formulary although existing supplies within acute trusts can and should be used up.

The following NICE TAs have been incorporated into BSWformulary. **RED TLS:**

663	Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
664	Liraglutide for managing overweight and obesity
665	Upadacitinib for treating severe rheumatoid arthritis
666	Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma

What the BSW CCG formulary team are currently working on

- Working with BSW cardiology teams to write prescribing guidance to support the introduction of dapagliflozin for symptomatic chronic heart failure with reduced ejection fraction onto the formulary. Note: currently NOT included on BSWformulary for this indication.
- Producing a policy/pathway and prescribing criteria for use of melatonin.
- Working on building and improving the Paediatric formulary chapter.
- Reviewing formulary position of Cox-2 inhibitors.
- Producing a SCA for Midodrine (licensed) &/or Fludrocortisone (off-label) for orthostatic hypotension – Adults.
- Prescribing guidance on primary care management of chronic urticarial.
- Reviewing formulary application for Ferric maltol (Ferracru) and proposed pathway for its use.
- Working with AWP on an oral antipsychotic SCA.
- Updating the BSW primary care antibiotic guidance in line with NICE updates.

- Working to improve the understanding of the definition of the Traffic Light System and initiation of shared care prescribing, to improve engagement and adherence to the BSWformulary across primary and secondary care.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net